These findings collectively underscore MST1 as a promising therapeutic target for modulating NAFLD/NASH progression through its regulatory effects on cholesterol biosynthetic pathways and inflammatory–fibrotic cascades. Here, MST1 is linked to metabolic dysfunction-associated steatohepatitis.